What is Relmada Therapeutics, Inc.'s stock-based comp?

Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $956.2K in Q1 2026.

How has Relmada Therapeutics, Inc.'s stock-based comp changed year-over-year?

Relmada Therapeutics, Inc.'s stock-based comp decreased by 73.2% year-over-year, from $3.57M to $956.2K.

What is the long-term trend for Relmada Therapeutics, Inc.'s stock-based comp?

Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock-based comp has grown at a -22.2% compound annual growth rate (CAGR), from $40.49M to $14.81M.

Relmada Therapeutics, Inc. RLMD Stock-Based Comp

Stock-Based Comp at other companies

Ford Motor CompanyF

$110M-9.1%

Trane TechnologiesTT

$26.8M+20.7%

EVR

EvergyEVRG

$5.6M+24.4%

SBA CommunicationsSBAC

$18.94M+20.5%

The Carlyle GroupCG

$119.8M+15.7%

ROP

Roper Technologies, Inc.ROP

$52.6M+35.6%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s stock-based comp?: Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $956.2K in Q1 2026.
How has Relmada Therapeutics, Inc.'s stock-based comp changed year-over-year?: Relmada Therapeutics, Inc.'s stock-based comp decreased by 73.2% year-over-year, from $3.57M to $956.2K.
What is the long-term trend for Relmada Therapeutics, Inc.'s stock-based comp?: Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock-based comp has grown at a -22.2% compound annual growth rate (CAGR), from $40.49M to $14.81M.